van der Ende A, van der Hulst R W, Dankert J, Tytgat G N
University of Amsterdam, Department of Medical Microbiology, The Netherlands.
Aliment Pharmacol Ther. 1997 Apr;11 Suppl 1:55-61. doi: 10.1046/j.1365-2036.11.s1.10.x.
Antimicrobial treatment of Helicobacter pylori is the proper management strategy in patients with ulcers. A high rate of H. pylori reinfection after successful eradication therapy however, may give rise to ulcer recurrence. The risk of reinfection, depending on the prevalence and the rate of acquisition of H. pylori infection, varies with socioeconomic status, age and geographical location. The rate of reinfection may vary in a similar way. The available data in the literature reveal that reinfection by H. pylori is low or absent in developed countries and may be lower than the initial rate of acquisition. In addition, reported cases of H. pylori reinfection are often cases of recrudescent H. pylori infection. Acquisition rate in developing countries is high, so the reinfection rate is expected to be higher than in developed countries. However, studies discriminating reinfection from recrudescence are lacking and therefore more data from developing regions are needed to settle if 'cured once, cured forever' holds true.
对溃疡患者进行幽门螺杆菌抗菌治疗是恰当的管理策略。然而，成功根除治疗后幽门螺杆菌再感染率较高，可能导致溃疡复发。再感染风险取决于幽门螺杆菌感染的流行率和获得率，因社会经济地位、年龄和地理位置而异。再感染率可能也以类似方式变化。文献中的现有数据表明，在发达国家，幽门螺杆菌再感染率较低或不存在，且可能低于初始获得率。此外，报告的幽门螺杆菌再感染病例往往是幽门螺杆菌感染复发的病例。发展中国家的获得率较高，因此预计再感染率高于发达国家。然而，缺乏区分再感染与复发的研究，因此需要来自发展中地区的更多数据来确定“一劳永逸治愈”是否成立。
